bioAffinity Technologies
BIAF
About: bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
Employees: 57
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
0% more funds holding
Funds holding: 17 [Q1] → 17 (+0) [Q2]
2.01% less ownership
Funds ownership: 3.29% [Q1] → 1.27% (-2.01%) [Q2]
21% less capital invested
Capital invested by funds: $132K [Q1] → $104K (-$28.4K) [Q2]
Financial journalist opinion
Based on 3 articles about BIAF published over the past 30 days
